Human Normal Immunoglobulin

Human normal immunoglobulin is a purified preparation of predominantly immunoglobulin G (IgG) antibodies obtained from the plasma of healthy human donors. It belongs to the class of human immunoglobulin preparations and is used either to replace missing or inadequate antibodies or, at higher doses, to modify abnormal immune responses. The exact mechanism varies with the clinical indication. In antibody deficiency, administered IgG provides passive antibodies that help protect against infections. At immunomodulatory doses, multiple mechanisms may contribute, including modulation of Fc-receptor activity, complement pathways, inflammatory mediators, and pathogenic autoantibodies. Depending on the formulation, human normal immunoglobulin may be administered intravenously, subcutaneously, or, for certain preparations, intramuscularly. Intravenous immunoglobulin (IVIG) is commonly used when rapid systemic exposure is required, while subcutaneous immunoglobulin (SCIG) can provide ongoing replacement therapy and may be suitable for home administration in selected patients. Human normal immunoglobulin is clinically important because it can restore protective antibody levels in people with primary or secondary antibody deficiency and can provide immunomodulatory treatment for several immune-mediated disorders. Products and approved indications vary between regulatory jurisdictions and individual formulations.

Human normal immunoglobulin preparations were developed from pooled plasma to provide concentrated IgG for antibody replacement and immune modulation. Modern manufacturing uses donor screening, plasma testing, purification and validated viral-reduction or inactivation processes to reduce the risk of transmission of infectious agents. Regulatory authorities have established product-specific standards and clinical guidance rather than treating human normal immunoglobulin as a single molecule with one universal indication. The European Medicines Agency has maintained core product-characteristic guidance for intravenous human normal immunoglobulin, with the current effective IVIG revision becoming legally effective on 1 January 2022; the EMA also adopted a revised core guideline for subcutaneous and intramuscular human normal immunoglobulin in 2026. Individual products have separate national or European marketing authorisations and may have different approved indications. In India, human normal immunoglobulin products are regulated as blood-derived biological products under the national regulatory framework, with CDSCO reviewing product quality, safety and clinical-development requirements. Clinical development programs have supported antibody-replacement therapy as well as immunomodulatory indications including immune thrombocytopenia, Kawasaki disease, Guillain–Barré syndrome, CIDP and other immune-mediated conditions.

Human normal immunoglobulin has two broad clinical roles: antibody replacement and immunomodulation. Replacement therapy is used in primary immunodeficiency syndromes with impaired antibody production and in selected secondary immunodeficiencies associated with severe or recurrent infections and inadequate antibody responses. Depending on the specific IVIG product, immunomodulatory indications can include primary immune thrombocytopenia, Guillain–Barré syndrome, Kawasaki disease, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and selected other immune-mediated disorders. Some formulations have additional approved indications, and the exact indication varies by product and jurisdiction. Immunoglobulin may be used alone or alongside other therapies depending on the disease; for example, it may be combined with corticosteroids or other immunosuppressive treatment when clinically appropriate. It is not interchangeable with disease-specific vaccines or targeted biologic therapies, and treatment selection should be based on the approved indication and individual clinical circumstances.

Administration and dosing depend on the formulation, route, indication, body weight, clinical response and product-specific prescribing information. IVIG is administered by intravenous infusion, while SCIG is administered under the skin at repeated intervals; some human normal immunoglobulin preparations are also approved for intramuscular administration. For antibody replacement, treatment is generally individualized to maintain adequate IgG trough concentrations and reduce the frequency or severity of infections; a loading dose may be followed by regular maintenance doses. Some SCIG replacement regimens use an initial dose followed by cumulative monthly dosing adjusted to clinical response and IgG trough levels. Immunomodulatory regimens generally use higher doses administered over one or several days, with the schedule determined by the underlying condition and approved product information. Infusion rates are usually increased gradually according to tolerance, particularly during initial treatment. Treatment duration may be long-term for antibody deficiency, whereas immunomodulatory therapy may be given as a defined course or repeated according to disease activity and response.

Common adverse effects of human normal immunoglobulin are usually mild and transient but vary according to the formulation and route. They may include headache, chills, fever, fatigue, nausea, vomiting, dizziness, back pain and infusion-related discomfort. Local reactions such as pain, redness, swelling, itching or tenderness can occur with subcutaneous administration. Infusion-related symptoms are more likely when treatment is started or when infusion rates are increased rapidly and may improve when the infusion is slowed or temporarily interrupted. Patients should report persistent or troublesome symptoms to their healthcare professional, particularly during the first treatment sessions.

Important but uncommon risks include severe hypersensitivity or anaphylactic reactions, thromboembolic events, acute kidney injury, hemolysis and aseptic meningitis. Rare pulmonary complications, including transfusion-related acute lung injury-like reactions, have also been reported with immunoglobulin products. Patients with risk factors for thrombosis, renal impairment, diabetes, dehydration, cardiovascular disease, advanced age or hyperviscosity require appropriate assessment before treatment. High-dose or rapidly administered IVIG may increase the risk of adverse reactions, so infusion should follow the product-specific rate recommendations. Human normal immunoglobulin is contraindicated in patients with a history of severe hypersensitivity to the active substance or relevant excipients, with additional contraindications depending on the formulation. Treatment should be slowed or stopped when clinically significant infusion or hypersensitivity reactions occur.

Before treatment, clinicians should review the indication, previous immunoglobulin exposure, history of hypersensitivity, renal function, thrombotic risk, hydration status and relevant baseline laboratory results. Patients with IgA deficiency and antibodies against IgA may require particular caution because some immunoglobulin preparations contain small amounts of IgA. Immunoglobulin therapy can interfere with the response to certain live attenuated vaccines, including measles-containing vaccines, because passively transferred antibodies may reduce vaccine effectiveness; vaccination timing should therefore be planned according to the specific product and vaccine. Classic metabolic drug interactions are generally uncommon because human normal immunoglobulin is a biological antibody preparation rather than a conventionally metabolised small-molecule drug. However, concomitant therapies and the underlying immune disorder should be considered when interpreting laboratory tests and assessing treatment response.

Confirm the indication and select a formulation with an appropriate approved route and concentration before administration. Establish relevant baseline information, including infection history and IgG levels for replacement therapy, while assessing renal function, hydration and thrombotic risk before IVIG when clinically appropriate. During infusion, follow the product-specific rate escalation schedule and observe the patient for infusion reactions, particularly during the first administration or after a prolonged treatment interval. For SCIG, ensure patients or caregivers receive appropriate training for home administration, injection-site rotation and management of missed doses or adverse reactions. Monitor IgG trough levels and infection frequency in replacement therapy, while immunomodulatory treatment should be assessed using disease-specific clinical and laboratory measures. Pharmacists should also verify storage requirements, product concentration, batch documentation and compatibility instructions, as different immunoglobulin products are not necessarily interchangeable.